Invitrogen Renews, Expands License and Supply Agreement with Luminex

  
    
  
  
    
      Invitrogen Corporation (NASDAQ: IVGN), a provider of essential life 
      science technologies for research, production and diagnostics, and 
      Luminex Corporation (NASDAQ: LMNX), today announced the renewal and 
      expansion of Invitrogen’s license and supply 
      agreement for Luminex’s multiplexed analyte 
      detection technology and systems. The new agreement extends the lifetime 
      of the license and provides Invitrogen with access to Luminex’s 
      next-generation multiplex detection platforms.
    
    
      xMAP® Technology and Luminex instrument 
      platforms use proprietary microspheres - micron-sized beads - encoded 
      with combinations of spectrally distinct fluorescent dyes to rapidly and 
      reproducibly determine the relative concentrations of many different 
      proteins or peptides at the same time in the same sample.
    
    
      Invitrogen offers more than 200 assays based on xMAP Technology, 
      comprising the most comprehensive multiplex protein assay menu in life 
      sciences for cellular pathway and disease analysis. Invitrogen also has 
      a large number of new multiplexed assays in its product development 
      pipeline to expand the number of targets accessible to scientists. The 
      company will offer custom assay development services using the 
      next-generation platform that complement its existing service of rapid, 
      affordable multiplex assay development on the original Luminex platform.
    
    
      “We are pleased with this new agreement and 
      committed to our relationship with Luminex,” 
      said Kip Miller, Invitrogen’s Senior Vice 
      President, BioDiscovery. “It is another step 
      in our strategy of building on our position as the leading cell biology 
      reagent provider to offer our customers integrated systems and solutions.”
    
    
      “We believe the extension of the agreement is 
      beneficial for both companies, as Luminex has quickly become a standard 
      in the industry for multiplexing and Invitrogen has the ability to offer 
      the broadest array of content for this important platform,” 
      added August Sick, Invitrogen Vice President and General Manager, 
      Cellular Analysis Business Unit. “The assays 
      we will develop on Luminex’s next-generation 
      platform will further accelerate drug discovery and cellular analysis.”
    
    
      “Luminex is pleased to extend and expand our 
      relationship with Invitrogen,” said Doug 
      Bryant, executive vice president and chief operating officer of Luminex. “Partnering 
      with innovative leaders such as Invitrogen is a key element in our 
      business strategy. We look forward to a valuable, long-term 
      collaboration with Invitrogen.”
    
    
      About Invitrogen
    
    
      Invitrogen Corporation (Nasdaq:IVGN) provides products and services that 
      support academic and government research institutions and pharmaceutical 
      and biotech companies worldwide in their efforts to improve the human 
      condition. The company provides essential life science technologies for 
      disease research, drug discovery, and commercial bioproduction. 
      Invitrogen's own research and development efforts are focused on 
      breakthrough innovation in all major areas of biological discovery 
      including functional genomics, proteomics, stem cells, cell therapy and 
      cell biology -- placing Invitrogen's products in nearly every major 
      laboratory in the world. Founded in 1987, Invitrogen is headquartered in 
      Carlsbad, California, and conducts business in more than 70 countries 
      around the world. The company employs approximately 4,700 scientists and 
      other professionals and had revenues of approximately $1.3 billion in 
      2007. For more information, visit www.invitrogen.com.
    
    
      About Luminex Corporation
    
    
      Luminex Corporation develops, manufactures and markets proprietary 
      biological testing technologies with applications throughout the 
      diagnostic and life sciences industries. The Company’s 
      xMAP® multiplex solutions include an 
      open-architecture, multi-analyte technology platform that delivers fast, 
      accurate and cost-effective bioassay results to markets as diverse as 
      pharmaceutical drug discovery, clinical diagnostics and biomedical 
      research, including the genomics and proteomics research markets. The 
      Company’s xMAP technology is sold worldwide 
      and is already in use in leading clinical laboratories as well as major 
      pharmaceutical, diagnostic and biotechnology companies. Further 
      information on Luminex Corporation or xMAP technology can be obtained at www.luminexcorp.com.
    
    
      Safe Harbor Statement
    
    
      Certain statements contained in this press release are considered 
      "forward-looking statements" within the meaning of the Private 
      Securities Litigation Reform Act of 1995, and it is Invitrogen's intent 
      that such statements be protected by the safe harbor created thereby. 
      Forward-looking statements include, but are not limited to: 1) the 
      second generation platform will simplify and automate the assays by 
      eliminating time- and resource-consuming filtering and washing steps 
      from the sample preparation procedure; 2) the existing assays will be 
      converted to the new magnetic bead based platform; 3) the company will 
      offer custom assay development services using the new platform to 
      complement its existing service of rapid, affordable multiplex assay 
      development on the original Luminex platform.
    
    
      Potential risks and uncertainties include, but are not limited to: a) 
      the assays based on this platform may or may not comprise the most 
      comprehensive multiplex protein assay menu in life sciences for cellular 
      pathway and disease analysis; b) Invitrogen may or may not have a large 
      number of new multiplexes in its product development pipeline to expand 
      the number of targets accessible to scientists; and the risks that the 
      market will not accept the companies’ 
      products and services, or that the companies will be unsuccessful in 
      their efforts to develop new products and services, as well as other 
      risks and uncertainties detailed from time to time in Invitrogen's 
      Securities and Exchange Commission filings.